170
Participants
Start Date
June 8, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2027
HS-20093
IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
RECRUITING
Peking University People's Hospital, Beijing
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
First Affiliated Hospital, Sun Yat-Sen University, Guangzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Chinese PLA General Hospital of Eastern Theater Command, Nanjing
RECRUITING
Shanghai 6th People's Hospital, Shanghai
RECRUITING
Shanghai General Hospital, Shanghai
RECRUITING
Tianjin Cancer Hospital, Tianjin
RECRUITING
Henan Cancer Hospital, Zhengzhou
Hansoh BioMedical R&D Company
INDUSTRY